<DOC>
	<DOCNO>NCT01802684</DOCNO>
	<brief_summary>Evaluation feasibility add aflibercept oxaliplatin-based regimen rather continuous administration chemotherapy progression , order decrease risk severe toxicity .</brief_summary>
	<brief_title>OPTIMOX-aflibercept First-line Therapy Patients With Unresectable Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The addition aflibercept standard FOLFIRI regimen second-line therapy evaluate large phase III study ( EFC10262-VELOUR ) . This new combination significantly improve PFS ( 4.7 6.9 month , HR=0.76 ; P=.00007 ) OS ( 12.1 13.5 month , HR=0.82 ; P=.0032 ) . In evaluable population ( 86.5 % ) , tumor response rate also improve add aflibercept ( ORR=19.8 % [ 16.4-23.2 ] ) FOLFIRI regimen ( ORR=11.1 % [ 8.5-13.8 ] ) . This trial evaluate feasibility add aflibercept oxaliplatin-based regimen first-line therapy , use OPTIMOX strategy rather continuous administration chemotherapy progression , order decrease risk severe toxicity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed date informed consent , willing able comply protocol requirement , 2 . Histologically proven adenocarcinoma colon and/or rectum , 3 . Metastatic disease confirm , 4 . No prior therapy metastatic disease ( case previous adjuvant therapy , interval end chemotherapy relapse must &gt; 6 month fluoropyrimidine alone &gt; 12 month oxaliplatinbased , bevacizumabbased , cetuximabbased therapy , 5 . Duly document inoperable metastatic disease , ie suitable complete carcinological surgical resection , 6 . At least one measurable evaluable lesion assess CTscan MRI ( Magnetic Resonance Imaging ) accord RECIST v1.1 , 7 . Age ≥18 year , 8 . ECOG Performance status ( PS ) 02 , 9 . Hematological status : neutrophil ( ANC ) ≥1.5x109/L ; platelet ≥100x109/L ; haemoglobin ≥9g/dL , 10 . Adequate renal function : serum creatinine level &lt; 150µM , 11 . Adequate liver function : serum bilirubin ≤3 x upper normal limit ( ULN ) , alkaline phosphatase &lt; 5xULN , 12 . Proteinuria &lt; 2+ ( dipstick urinalysis ) ≤1g/24hour , 13 . Baseline evaluation : clinical blood evaluation perform 2 week ( 14 day ) prior confirmation eligibility , tumor assessment ( chest X ray , CTscan MRI , evaluation nonmeasurable lesion ) 3 week ( 21 day ) prior confirmation eligibility , 14 . For female patient childbearing potential , negative serum urine pregnancy test within 1 week ( 7 day ) prior start study treatment , 15 . Female patient childbearing potential must commit use reliable effective method contraception trial least six month end study treatment . Females neither pregnant breastfeeding . Male patient partner childbearing potential must agree use effective contraception addition contraceptive method use partner trial least six month end study treatment . 16 . Registration national health care system ( CMU include France ) . 1 . History evidence upon physical examination CNS metastasis unless adequately treat ( e.g . non irradiated CNS metastasis , seizure control standard medical therapy ) , 2 . Exclusive bone metastasis , 3 . Uncontrolled hypercalcemia , 4 . Preexisting permanent neuropathy ( NCI grade ≥2 ) , 5 . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg despite optimal medical therapy ) , history hypertensive crisis , hypertensive encephalopathy , 6 . Concomitant unplanned antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy/ radioimmunotherapy ) , 7 . Treatment investigational medicinal product within 28 day prior study entry , 8 . Other serious uncontrolled nonmalignant disease , 9 . Other concomitant previous malignancy , except : i/ adequately treat insitu carcinoma uterine cervix , ii/ basal squamous cell carcinoma skin , iii/ cancer complete remission &gt; 5 year , 10 . Any serious uncontrolled nonmalignant disease , major surgery traumatic injury within last 28 day 11 . Patients know allergy excipient study drug , 12 . History myocardial infarction and/or stroke within 6 month prior study entry , 13 . Bowel obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>unresectable</keyword>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>OPTIMOX</keyword>
	<keyword>aflibercept</keyword>
</DOC>